November 10, 2026
First, the two questions:
1. Is metastatic progression solely from and defined by disseminated tumor cells, DTCs? Or, possible that EVs, exosomes, carry mRNA to distant sites to, over time, establish both a lineage of the primary TME and recruit multipotent progenitor, stem cells (eg BMDCs)? “Metastasis” of the TME.
2. Though is published that, even within the primary tumor, “mutations are random,” meaning no two cancer cells share identical DNA signature, do metastatic cancer cells share DNA structural evidence of clonality, or genotype origin, of the originating primary tumor, only that of the tissue origin of the originating primary tumor?
Why is this important?
Tumor Microenvironment, TME: It directly undermines, counters, the theory that Cancer is a “genetic” disease. DNA mutations occur as part of an amplified, extended, chronic inflammatory, wound-repair process, where cell death signaling (ROS) damage cell DNA, followed by the cell’s attempts (PARP) to repair the DNA, which results in a genetically unique, mutated hybrid DNA in the surviving cell.
Definition: If this process described is accurate, the definition of Cancer should be revised, better described as a “chronic inflammatory disease or Cancer environment” expressing the shared hallmarks of all cancers, signified by a mutated DNA phenotype.
Cure: If Cancer is actually an advanced or amplified version (mutated DNA) of a chronic inflammatory disease, sharing the hallmarks of other chronic inflammatory diseases, then decades of the failed “gold standard” of biopsy and invasive treatments must be reconsidered. And the prospect of “cure,” also be reconsidered.
Comprehensive Multi-Region Sampling Reveals Extensive Genomic Heterogeneity in Metastatic Prostate Cancer
Tumor Heterogeneity Selective Pressure – Why We Need New Targets?, 2023
Mutational Heterogeneity in Human Cancers: Origin and Consequences, 2010
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3375045
“The Wicha laboratory recently reported that breast cancers have two different pools of CSCs: (1) an ALDH1-positive population with an epithelial phenotype found in hypoxic areas of a tumor and (2) a CD24?/CD44+ population of cells at the invasive front of the tumor exhibiting a mesenchymal phenotype. Their study provided convincing evidence that both populations could convert into each other via EMT/MET transitions [116].”
Cancer Stem Cells, Cancer Cell Plasticity and Radiation Therapy, 2015
https://pmc.ncbi.nlm.nih.gov/articles/PMC4291301/
“Solid tumors are not simply clones of cancer cells. Instead, they are abnormal organs composed of multiple cell types and extracellular matrix. Some aspects of tumor development resemble processes seen in developing organs, while others are more akin to tissue remodeling. Some microenvironments, particularly those associated with tissue injury, are favorable for progression of mutant cells while others restrict it. Cancer cells can also instruct surrounding tissues to undergo changes that promote malignancy.”
Tumors as organs, 2010
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2905377/
Metastatic Polyclonality – Mutations Random
November 10, 2026
The AI Conversation
Polyclonal metastasis means a secondary tumor is founded by multiple genetically distinct cancer cell clones rather than the descendant of one single cell. This challenges the classical model, in which one aggressive cell escapes the primary tumor, circulates alone, and seeds a monoclonal (single-clone) metastasis[2].
How polyclonal metastases form
- Collective dissemination (cell clusters) — The best-characterized mechanism. Tumor cells break off as cohesive multicellular clusters or “emboli” that travel together in the bloodstream and land as a group[1]. Because the cluster contains several clones, the resulting metastasis is polyclonal from birth.
- Cooperative heterogeneity — Different clones contribute different functions. In the landmark breast-cancer work by Cheung et al., clusters contained two molecularly distinct subpopulations, with keratin-14–expressing (K14⁺) leader-like cells enabling the rest to colonize distant organs[2].
- Serial / multiple seeding — Repeated arrivals of different clones at the same site can also build up a polyclonal lesion, though lineage-tracing experiments showed this is not the main route in the PyMT breast model: staggered injections of differently labeled single cells produced zero multicolored metastases (0/64)[1].
Key evidence (Cheung et al., PNAS 2016)
Using multicolor lineage tracing (mTomato/eGFP mosaics) in MMTV-PyMT mouse tumors, most lung metastases contained both colors, proving multicellular seeding[1]. Direct observation confirmed polyclonal collective invasion strands, intravascular emboli, and circulating tumor cell (CTC) clusters enriched for K14⁺ cells[1]. Knocking down K14 abolished distant metastasis and disrupted effectors like Tenascin C, Jagged[1], and Epiregulin[2].
Why it matters clinically
| Feature | Monoclonal | Polyclonal |
|---|---|---|
| Seeding unit | Single cell | Cluster / multiple clones |
| Genetic diversity | Low | High |
| Therapy resistance risk | Lower | Higher (more targets to escape) |
| Growth advantage | None inherent | Clonal cooperation boosts colonization [2] |
- Evolutionary flexibility: More clones means more raw material for adaptation under treatment pressure.
- Seeding patterns vary by cancer type: Lineage-tracing studies find both monoclonal and polyclonal seeding depending on tumor context; e.g., a DMBA/TPA squamous skin carcinoma model showed predominantly polyclonal dissemination after surgical resection[4].
- CTC clusters as biomarkers: Detecting clustered CTCs in blood may flag patients prone to polyclonal, cooperative metastasis.
Want me to go deeper on the molecular drivers (K14, adhesion complexes, immune evasion via MHC-II loss), the phylogenetics of polyphyletic vs. monophyletic seeding, or therapeutic implications?
https://pmc.ncbi.nlm.nih.gov/articles/PMC4763783/ https://pmc.ncbi.nlm.nih.gov/articles/PMC4763783/ https://pure.johnshopkins.edu/en/publications/polyclonal-breast-cancer-metastases-arise-from-collective-dissemi-2/
https://www.cell.com/trends/cancer/fulltext/S2405-8033(21)00228-4
Does these characteristics better support that the disseminated tumor cell carries the ‘fingerprint” of a cancerous environment, rather than that of a cancer genotype, as in a “phenotype metastasis” and not “genotype?” Is there any evidence that supports that any “clonality” originates from the cancer mutation and not in the DNA of the originating tissue or organ?
This is a sophisticated question that touches on the Hallmarks of Cancer, clonal evolution theory, and the ongoing debate between the genetic vs. epigenetic/ecological origins of metastasis.
Here is how the current evidence breaks down:
1. “Phenotype” vs. “Genotype”: The “Fingerprint” of the Environment
Your hypothesis—that metastasis is driven by a “phenotypic fingerprint” of the environment rather than just the genotype—is strongly supported by the concept of collective dissemination and clonal cooperation.
- Evidence for Environmental “Fingerprinting”:
- The discovery that metastases are often polyclonal (seeded by multiple clones) suggests that a single cell’s genotype (DNA sequence) is not enough to guarantee metastatic success. Instead, the collective behavior of the cluster—which is dictated by cell-cell communication, adhesion, and response to local microenvironmental cues (the “fingerprint”)—is what drives colonization.
- K14+ Leader Cells: In breast cancer, metastasis is driven by a specific subpopulation (K14+) that creates a “permissive” environment for other clones. These cells remodel the extracellular matrix and secrete factors (like Tenascin C and Jagged1) that facilitate survival in the bloodstream and distant organs. This is a phenotypic adaptation to the environment, not just a genetic mutation.
- Clonal Cooperation: If metastasis were purely “genotype-driven,” you would expect only the single “fittest” genetic clone to survive. The fact that multiple distinct clones cooperate (with some providing leadership and others providing proliferation or immune evasion) suggests that phenotypic plasticity and ecological interaction are critical for metastatic success.
- However, Genotype Still Matters:
- While phenotype is crucial, the “fingerprint” is still encoded by the genotype. Mutations in genes like TP53, KRAS, or PIK3CA create the genetic instability that allows cells to adopt these cooperative phenotypes. Without these genetic drivers, the cells would likely undergo apoptosis or senescence rather than forming a metastatic cluster.
2. Does “Clonality” Originate from Cancer Mutation or Normal Tissue DNA?
This question addresses the origin of clonal expansion. The evidence overwhelmingly supports that clonality originates from cancer mutations, not from the normal DNA of the originating tissue.
- Evidence for Mutation-Driven Clonality:
- Somatic Mutations as Clonal Markers: Metastases and primary tumors share somatic mutations (e.g., specific SNPs, copy-number variations) that are absent in the patient’s normal, non-cancerous tissue. This proves that the “clonal expansion” is driven by these specific genetic alterations.
- Lineage Tracing: Studies using multicolor lineage tracing (e.g., in mouse models) show that metastases arise from specific clones that have acquired distinct genetic labels (e.g., different fluorescent markers due to Cre-lox recombination). These labels are inherited by the metastatic cells, proving that the clonal expansion is genetically determined.
- Phylogenetic Trees: Genomic sequencing of primary and metastatic tumors allows researchers to build phylogenetic trees. These trees show that metastatic clones branch off from specific mutated subclones within the primary tumor, not from the normal tissue background.
- Why Normal Tissue DNA Doesn’t Drive Clonality:
- Normal tissue cells do not undergo uncontrolled clonal expansion. They are regulated by homeostatic mechanisms (contact inhibition, DNA repair, immune surveillance).
- Cancer mutations (e.g., in APC, KRAS, TP53) bypass these controls, allowing a single mutated cell to expand into a clone that outcompetes its neighbors. This is the definition of clonal evolution.
Summary Table
| Feature | Supports “Phenotype/Environment” | Supports “Genotype/Mutation” |
|---|---|---|
| Polyclonal Metastasis | Yes: Multiple clones cooperate; collective behavior matters | Yes: Clones are defined by shared mutations |
| Clonal Expansion | Phenotypic plasticity allows adaptation | Driven by somatic mutations (e.g., TP53) |
| Metastatic Success | Dependent on microenvironmental cues (K14+, ECM remodeling) | Dependent on genetic drivers of invasion/metastasis |
| Origin of Clonality | Not driven by normal tissue DNA; normal cells don’t expand clonally | Originates from specific cancer mutations |
Conclusion
- Metastasis is both: It is not “either/or.” The genotype (cancer mutations) provides the potential for clonal expansion and metastatic behavior, while the phenotype (environmental adaptation, collective dissemination) provides the mechanism for successful colonization.
- Clonality originates from mutations: There is no evidence that normal tissue DNA drives clonal expansion. Clonality is a hallmark of cancer, driven by somatic mutations that bypass normal growth controls.
Polyclonal breast cancer metastases arise from collective dissemination of K14+ clusters, 2016
https://pmc.ncbi.nlm.nih.gov/articles/PMC4763783/
Hallmarks of Cancer: New Dimensions, 2022
https://aacrjournals.org/cancerdiscovery/article-lookup/doi/10.1158/2159-8290.CD-21-1059
Is it possible that the somatic mutations shared in mutated subclones also be present in the mRNA carried by extracellular vesicles secreted by the primary tumor?
Yes, absolutely. The somatic mutations found in tumor cells are indeed present in the cargo of extracellular vesicles (EVs), such as exosomes, secreted by the primary tumor.
This is a well-established mechanism in cancer biology and is the foundation for “liquid biopsies.”
How This Works
- Mutation Origin: The somatic mutations (e.g., in TP53, KRAS, BRCA1) occur in the nuclear DNA or mitochondrial DNA of the cancer cells in the primary tumor.
- RNA Transcription: These mutated DNA sequences are transcribed into mutated mRNA (and other non-coding RNAs like miRNA).
- Packaging into EVs: The tumor cells actively package these mutated RNA species into extracellular vesicles (exosomes/microvesicles).
- Secretion: These EVs are released into the local microenvironment and eventually enter the bloodstream or other bodily fluids.
- Detection: Because the mRNA inside the EVs carries the same genetic mutations as the parent tumor cell, it can be detected in a patient’s blood.
Key Evidence & Implications
- Liquid Biopsies: Clinicians can draw a patient’s blood, isolate EVs (exosomes), and sequence the RNA or DNA within them to detect tumor-specific mutations without performing a surgical biopsy. This is used to monitor treatment response and detect recurrence.
- Pre-Metastatic Niche Formation: Primary tumor-derived EVs travel to distant organs and carry mutated RNA/proteins that can reprogram distant cells (e.g., fibroblasts, immune cells) to create a “pre-metastatic niche.” This prepares the distant site for incoming circulating tumor cells, effectively “informing” the future metastatic site about the primary tumor’s genetic identity.
- Clonal Heterogeneity: Because primary tumors are heterogeneous, different EV subpopulations may carry RNA from different mutated subclones. This allows researchers to map the clonal architecture of the tumor by analyzing EV cargo, revealing which subclones are actively secreting and potentially which ones are most aggressive.
Important Nuance: mRNA vs. DNA in EVs
- mRNA in EVs: Yes, mutated mRNA is carried. This can be translated into mutated proteins by recipient cells, potentially altering their behavior.
- DNA in EVs: Surprisingly, some studies also show that tumor-derived DNA (fragments of the original mutated genomic DNA) can be found in EVs or as ctDNA (circulating tumor DNA) in the blood. This ctDNA is often not inside EVs but is free-floating, though EVs can also carry DNA.
Conclusion
The somatic mutations shared by mutated subclones in the primary tumor are definitely present in the mRNA (and sometimes DNA) carried by extracellular vesicles. This is a critical mechanism for intercellular communication and metastatic preparation, and it is directly exploited in modern liquid biopsy diagnostics.
Circulating tumor cells and exosomes as liquid biopsy markers, 2026
https://link.springer.com/article/10.1186/s43556-025-00257-8
Extracellular vesicles in the pre-metastatic niche, 2019
Exosome-mediated transfer of mRNA and miRNA between cells, 2007
Brave AI search:
Extracellular vesicles in the pre-metastatic niche
Extracellular vesicles (EVs), particularly those derived from tumor cells, are critical mediators in the formation of the pre-metastatic niche (PMN), a supportive microenvironment prepared in distant organs to facilitate metastatic colonization.
These vesicles travel from the primary tumor to secondary sites, where they reprogram host stromal and immune cells through the transfer of bioactive cargo, including mRNAs, microRNAs, proteins, and metabolites. This conditioning process involves several key mechanisms:
- Extracellular Matrix (ECM) Remodeling: EVs promote the deposition of fibronectin, collagen, and tenascin C, creating a permissive physical structure for incoming tumor cells.
- Angiogenesis and Permeability: They enhance vascular permeability and stimulate the growth of new blood vessels, improving nutrient supply and access for disseminated tumor cells.
- Immunosuppression: EVs recruit and polarize immune cells, such as macrophages, toward an M2-like phenotype that suppresses anti-tumor immunity and supports tumor growth.
- Organotropism: Specific EV cargo, such as unique integrin combinations, determines which organs (e.g., liver, lung, brain, bone) become favorable sites for metastasis by targeting specific resident cell types.
Ultimately, tumor-derived EVs effectively “fertilize the soil” by establishing a hospitable niche that allows circulating tumor cells to survive, proliferate, and establish secondary metastatic lesions.
Extracellular vesicle-mediated pre-metastatic niche formation via altering host microenvironments, 2024
https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1367373/full
Pre-metastatic Niche Formation in Different Organs Induced by Tumor Extracellular Vesicles, 2021
https://pmc.ncbi.nlm.nih.gov/articles/PMC8489591/
Weaving the nest: extracellular matrix roles in pre-metastatic niche formation, 2023
https://pmc.ncbi.nlm.nih.gov/articles/PMC10282420/
Contribution of tumor-derived extracellular vesicles in the establishment of the pre-metastatic niche: lessons learned from past experimentations and future directions, 2026
https://pmc.ncbi.nlm.nih.gov/articles/PMC12967406/
Brave AI search:
Exosome-mediated transfer of mRNA and miRNA between cells
Exosomes are extracellular vesicles that facilitate intercellular communication by transferring functional mRNA and microRNA (miRNA) between donor and recipient cells. This process, known as the transfer of “exosomal shuttle RNA” (esRNA), allows for the regulation of gene expression and protein synthesis in target cells, even across different species.
- Functional Impact: Transferred mRNA can be translated into new proteins within recipient cells, while exosomal miRNAs can silence specific target mRNAs, thereby altering cellular behavior and signaling pathways.
- Selective Packaging: The RNA content of exosomes does not simply mirror the donor cell’s cytoplasm; instead, specific transcripts are actively and selectively loaded into exosomes, suggesting a sophisticated mechanism for targeted genetic exchange.
- Biological Roles: This mechanism plays critical roles in immune responses, such as the unidirectional transfer of miRNAs from T cells to antigen-presenting cells, and is implicated in cancer progression, where tumor-derived exosomes modify the microenvironment to promote metastasis.
- Therapeutic Potential: Due to their natural ability to deliver nucleic acids while protecting them from degradation, exosomes are being investigated as delivery vectors for RNA-based therapies, including the introduction of siRNAs or mRNAs for gene silencing or replacement.
From article:
Exosomes are vesicles of endocytic origin released by many cells. These vesicles can mediate communication between cells, facilitating processes such as antigen presentation. Here, we show that exosomes from a mouse and a human mast cell line (MC/9 and HMC-1, respectively), as well as primary bone marrow-derived mouse mast cells, contain RNA. Microarray assessments revealed the presence of mRNA from approximately 1300 genes, many of which are not present in the cytoplasm of the donor cell. In vitro translation proved that the exosome mRNAs were functional. Quality control RNA analysis of total RNA derived from exosomes also revealed presence of small RNAs, including microRNAs. The RNA from mast cell exosomes is transferable to other mouse and human mast cells. After transfer of mouse exosomal RNA to human mast cells, new mouse proteins were found in the recipient cells, indicating that transferred exosomal mRNA can be translated after entering another cell. In summary, we show that exosomes contain both mRNA and microRNA, which can be delivered to another cell, and can be functional in this new location. We propose that this RNA is called “exosomal shuttle RNA” (esRNA).
Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells, 2007
https://pubmed.ncbi.nlm.nih.gov/17486113/
Exosome and microRNA transfer from a paracrine & endocrine communication to cross-kingdom communication
https://www.gene-quantification.de/exosomes-microrna-transfer.html
From article:
Exosomes are 40–100 nm nano-sized vesicles that are released from many cell types into the extracellular space. Such vesicles are widely distributed in various body fluids. Recently, mRNAs and microRNAs (miRNAs) have been identified in exosomes, which can be taken up by neighboring or distant cells and subsequently modulate recipient cells. This suggests an active sorting mechanism of exosomal miRNAs, since the miRNA profiles of exosomes may differ from those of the parent cells. Exosomal miRNAs play an important role in disease progression, and can stimulate angiogenesis and facilitate metastasis in cancers.
Exosome and Exosomal MicroRNA: Trafficking, Sorting, and Function,
2015
https://www.sciencedirect.com/science/article/pii/S167202291500011X